Regulation
Federal Cannabis Review Reaches Milestone as HHS Recommends Schedule III Reclassification
The scheduling review, prompted by Pres. Biden in October, could reshape the cannabis policy landscape in the U.S. Now, the DEA will decide.
At FDLI Conference, State and Federal Regulators Convene Over Cannabis, CBD, Equity, and Animals
The two-day FDLI conference focused on thorny questions in cannabis regulation, and included the FDA and other regulators.
As FDA Looks to Congress for CBD Regs, it Elaborates on Potential Paths Forward
On Thursday, the FDA pushed its desire to work with Congress on cannabinoid product rules, including delta-8 THC.
CBD’s Potential for Reproductive Harms Among “Big Reasons” Behind FDA’s Punt on Rules
The FDA is seeking a “harm reduction framework” as it works with Congress on a path for CBD, according to the agency’s Cannabis Product Committee lead.
Amid Booming Cannabis Industry, State Insurance Regulators Call for “Safe Harbor” in New White Paper
A working group of the National Association of Insurance Commissioners plans to present the final paper at the Association’s Summer National Meeting in August.
Top “Threat” to Legal Cannabis? Confusion Over Intoxicating Hemp Products, Says Head of CANNRA
Will the 2023 Farm Bill fix some of the confusion caused by the 2018 version that legalized hemp? State regulators and industry regulators hope Congress acts fast.
FDA’s Cannabis Advisor: Approach to CBD Rules Shouldn’t Let “Perfect be the Enemy of the Good”
Norman Birenbaum spoke about the FDA’s cannabis-related efforts during a discussion on Thursday hosted by the Council for Federal Cannabis Regulation.
Exclusive: Cannabis Wire Goes One-on-One with FDA’s Leading Advisor on Cannabis
Norm Birenbaum, the FDA’s senior public health advisor on cannabis, spoke with Cannabis Wire about his new role and his priorities for 2023.
FDA Announces Plan to Work with Congress on “New” Path for CBD Products
The cannabis industry has long-awaited rules from the FDA to guide the CBD industry. Now, it’s up to Congress.
Here’s the FDA’s Final Guidance on Cannabis and Clinical Research
The FDA’s long-awaited guidance for non-medical products containing CBD, which are already widely available despite being unregulated, is still in the works.
Attorneys General Call on Congress to Address Cannabis Edibles Packaged Like Popular Brands
The group wants Congress to step in and pass legislation that could curb so-called “copycat” THC products, which are particularly appealing to kids.
Cannabis and Isomers like Delta-8 in Spotlight at Federal Testing Meeting
During the SAMHSA Drug Testing Advisory Board meeting, officials discussed emerging trends with cannabis-derived isomers.
FDA Officials Wrestle with CBD in Day-Long Meeting on Science “Challenges”
The FDA still has more questions than answers on CBD, but it is making strides on conducting the research and collecting the data needed to release product regulations.
FDA Meeting Will Spotlight “Challenges” With Cannabis Compounds in Foods and Supplements
The meeting, which will use cannabinoids as a “case study” in assessing the “safety” of certain foods and supplements, comes as the FDA wrestles with rulemaking for CBD products.
FDA Warns Companies Against CBD in Animal Products
While cannabidiol products aren’t yet FDA approved for humans or animals, that hasn’t stopped plenty of sellers from marketing their products to treat, for example, animals’ anxiety.
Cannabis Testing, Research, and the Future of Federal Regulation
A two-day event hosted by the Food and Drug Law Institute highlighted cannabis regulatory headaches, including delta-8 THC and a lack of uniformity in lab testing.
